Trial · NCT03320330
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities | Part A: 20 mg/kg (Phase 1) | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities | Part A PK: 20 mg/kg (Expansion) | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities | Part B: 20 mg/kg (Phase 2) | 1 | Participants | ||
| Patients Who Had Grade 3 or Above Toxicities With the Three Attributions, 'DEFINITE', 'POSSIBLE','PROBABLE' | Part A: 20 mg/kg (Phase 1) | 0 | Participants | ||
| Patients Who Had Grade 3 or Above Toxicities With the Three Attributions, 'DEFINITE', 'POSSIBLE','PROBABLE' | Part A PK: 20 mg/kg (Expansion) | 1 | Participants | ||
| Patients Who Had Grade 3 or Above Toxicities With the Three Attributions, 'DEFINITE', 'POSSIBLE','PROBABLE' | Part B: 20 mg/kg (Phase 2) | 3 | Participants | ||
| Half-life | Part A: 20 mg/kg (Phase 1) | 281 | Standard Deviation 176 | hours | |
| Half-life | Part A PK: 20 mg/kg (Expansion) | 221 | Standard Deviation 48 | hours | |
| Half-life | Part B: 20 mg/kg (Phase 2) | 162 | Standard Deviation 64 | hours | |
| Time to Maximum Concentration (T Max) | Part A: 20 mg/kg (Phase 1) | 1.9 | Standard Deviation 1.1 | hours | |
| Time to Maximum Concentration (T Max) | Part A PK: 20 mg/kg (Expansion) | 1.7 | Standard Deviation 1 | hours | |
| Time to Maximum Concentration (T Max) | Part B: 20 mg/kg (Phase 2) | 1.7 | Standard Deviation 0.9 | hours | |
| Maximum Concentration (C Max) | Part A: 20 mg/kg (Phase 1) | 175 | Standard Deviation 78 | ug/ml | |
| Maximum Concentration (C Max) | Part A PK: 20 mg/kg (Expansion) | 203 | Standard Deviation 85 | ug/ml | |
| Maximum Concentration (C Max) | Part B: 20 mg/kg (Phase 2) | 168 | Standard Deviation 75 | ug/ml | |
| Area Under Curve (AUC) | Part A: 20 mg/kg (Phase 1) | 46913 | Standard Deviation 29902 | hr*ug/ml | |
| Area Under Curve (AUC) | Part A PK: 20 mg/kg (Expansion) | 41328 | Standard Deviation 9251 | hr*ug/ml | |
| Area Under Curve (AUC) | Part B: 20 mg/kg (Phase 2) | 36811 | Standard Deviation 17641 | hr*ug/ml | |
| Clearance | Part A: 20 mg/kg (Phase 1) | 40.03 | Standard Deviation 34.9 | ml/hr | |
| Clearance | Part A PK: 20 mg/kg (Expansion) | 13.4 | Standard Deviation 4.6 | ml/hr |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03320330/results